Unregistered User If this is not your name, click here.
		Contact Us | Order Now | Journals | Bookstore | Register a colleague
	Select a ChannelAcneAIDS and HIVAllergy OtherAlzheimer'sAnaesthesiology OtherAngina Pectoris/MIAnxietyArthritis OtherAsthmaBack PainBacterial InfectionsBladder CancerBone Marrow TransplantationBreast CancerCardiology OtherCataractCell TransplantationCervical CancerCholesterol/Lipid disordersCirrhosisClinical PharmacologyColorectal CancerCongestive Heart FailureContact DermatitisContraceptionCOPDCystic FibrosisDental and Oral DisordersDepressionDermatology OtherDiabetesDialysisEating DisordersElbowEmergency MedicineEndocrinology OtherEpilepsyErectile DysfunctionFibromyalgiaGastro OtherGeneticsGenitourinary OtherGeriatricsGERD/GastritisGlaucomaH. Pylori/UlcerHaematology OtherHair LossHeadachesHepa/Biliary OtherHepatitisHipHRTHypertensionIBDImmunologyInfectious OtherInfertilityIntensive CareIrritable Bowel SyndromeKneeLeukemiasLiver CancerLung CancerLupusLymphomasMelanomaMenopauseMultiple Sclerosis Nephrology OtherNeurologic OtherNutritional / Metabolic OtherOb/Gyn OtherObesityOncology OtherOphth. OtherOphthalmic SurgeryOrgan TransplantationOrthopaedics OtherOsteoarthritisOsteoporosisOtitisOtorhino. OtherOvarian CancerPaediatricsPainPancreatic CancerParkinson'sPregnancyProstate CancerPsychiatry OtherPulmonary OtherRadiologyRenal CancerRenal FailureRespiratory InfectionsRheumatoid arthritisRheumatology OtherRhinitisSchizophreniaShoulderSleep ApnoeaSleep DisordersSpineStrokeSTDsSurgeryThyroid DisordersTransfusionTransplant Surgery OtherTraumaUrinary IncontinenceUrinary tract infectionsVaccinologyVascular DisordersViral Infections

SEARCH   News Bookstore Medline The Web Meetings & Congresses Complete Doctor's Guide    EXPLORE :    All News   All Webcasts   All Cases   All Meetings & Congresses   All Medical Resources New drugs / indications English Dictionary Medical Dictionary Thesaurus Warning | Privacy | Awards  Favourite Journals  Click here to choose your favourite journals  Favourite Sites  Click here to choose your favourite sites  Languages  Select languageEnglishFrançais

ACOG: Overactive Bladder Drugs Appear Safe; Oxybutynin Outperforms Tolterodine By Ed Susman Special to DG News LOS ANGELES, CA -- May 10, 2002 -- Researchers comparing two drugs that are used to treat overactive bladder said the safety profile of oxybutynin and tolterodine appear similarly safe, but that oxybutynin reduces symptoms better than tolterodine. The findings were presented by Peter Sand, MD, of Northwestern University Medical School, Evanston, Illinois, here Thursday at the 50th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG). Dr. Sand and colleagues randomised 202 women with urge incontinence and urinary frequency them to receive 10 mg extended-release oxybutynin daily or 2 mg tolterodine bid. The patients were scrutinized by age group: younger than 65, between 65 and 74, and older than 74. Two-thirds of the patients were younger than 65. The 12-week trial, supported by ALZA Corporation on behalf of Crescendo Pharmaceuticals Corporation, Mountain View, California, showed that women reported better symptom relief with oxybutynin. "[Oxybutinin] was significantly more effective than [tolterodine] with regard to all of the efficacy parameters: urge incontinence, total incontinence, and micturition frequency in women," he said. Both drugs, however, were significantly effective in reducing the numbers of urge and total incontinence episodes and in micturition frequency from baseline to study end. Those results were statistically significant (p<0.001). For example, the number of incidents of urge incontinence was about 25 per week at baseline, a figure that dropped to 5.4 episodes per week with oxybutynin and 8.7 episodes per week with tolterodine. The difference between the two drugs was statistically significant (p=0.004). The drugs were generally well tolerated, Dr. Sand reported. For both drugs dry mouth was the most frequent complaint, especially among women younger than 65; headache was the second most frequent complaint. "The incidence of most adverse events was low and similar in both treatment groups and among three age groups," he said. "Adverse events were typically mild and resolved without sequelae," Dr. Sand said. E-mail this page to a friend or colleague! To print, use this version